Cargando…
Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
Herein, we report the case of a 48‐year‐old woman with metastatic thymoma who developed fulminant myositis with cardiotoxicity after one cycle of pembrolizumab treatment. She presented with severe muscle weakness and dyspnea, and her laboratory test results revealed increased muscle and cardiac enzy...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402350/ https://www.ncbi.nlm.nih.gov/pubmed/36034177 http://dx.doi.org/10.1002/rcr2.1025 |